Literature DB >> 7921428

Effect of chronic theophylline therapy on brain blood flow and function in adult asthmatics.

D L Bowton1, D A Stump, R Anderson.   

Abstract

The impact of theophylline therapy on neuropsychological (NP) function in adult asthmatics is unclear. Additionally, whether the previously demonstrated acute reduction in cerebral blood flow (CBF) persists with continued administration of theophylline, or whether accommodation develops, has not been previously reported. We examined the effects of chronic theophylline administration on CBF and NP function in adults with mild to moderate asthma. Sixty adult patients with mild to moderate asthma were entered into this double-blind, placebo-controlled, crossover, random sequence study. Subjects received theophylline or placebo for 6 wk interposed with a 2-wk washout period. At the conclusion of Week 1 and Week 6 of each drug phase, patients received NP testing, and CBF was determined using the 133Xenon washout method. Forty-three patients completed the study. Theophylline administration was associated with small (6%), but statistically significant, reductions in CBF after both 1 and 6 wk of treatment. No differences consequent to theophylline administration were observed in any of the tests of NP function after 1 or 6 wk of therapy. While CBF was decreased after theophylline, the changes were small compared with previously reported decrements in CBF immediately after theophylline administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921428     DOI: 10.1164/ajrccm.150.4.7921428

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  1 in total

1.  Altered Regional Cerebral Blood Flow of Right Cerebellum Posterior Lobe in Asthmatic Patients With or Without Depressive Symptoms.

Authors:  Yuqun Zhang; Yuan Yang; Ze Wang; Rongrong Bian; Wenhao Jiang; Yingying Yin; Yingying Yue; Zhenghua Hou; Yonggui Yuan
Journal:  Front Psychiatry       Date:  2018-05-28       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.